A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Clinical trial NCT03783403 · TERMINATED
Trial details
- NCT number
- NCT03783403
- Sponsor
- Celgene
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-01
- Primary completion
- 2024-08-05
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.